GlassScriptPhysician profile
Ramon E Ravelo
NPI 1437172426
$12,930.34
in general payments reported to CMS, 2019-2025
17 companies · $3,033 in 2025
The $3,033 reported for 2025 was more than what 89% of Addiction Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $152).
See the full distribution for Addiction Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,044 · 2020: $822 · 2021: $1,203 · 2022: $1,994 · 2023: $2,174 · 2024: $2,661 · 2025: $3,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,287 · Education: $580.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,287.46 |
| Education | $580.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $2,576.12 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Abbvie INC. | $2,248.45 | 2021-2025 | |
| Axsome Therapeutics, INC. | $1,501.78 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $1,298.12 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $1,272.57 | 2020-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $938.35 | 2019-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $736.70 | 2019-2025 | Trintellix |
| Allergan, INC. | $625.01 | 2019-2020 | |
| Lundbeck LLC | $520.67 | 2019-2025 | Abilify Asimtufii, Rexulti |
| Sunovion Pharmaceuticals INC. | $328.24 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $306.84 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $217.71 | 2025 | |
| Bausch Health US, LLC | $170.99 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $71.96 | 2024-2025 | Cobenfy |
| Validus Pharmaceuticals LLC | $68.76 | 2025 | Equetro, Raldesy |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $27.85 | 2025 | Spravato |
| Sumitomo Pharma America, INC. | $20.22 | 2023 | Latuda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramon Ravelo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.